Overview

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to determine the analgesic efficacy and safety of ALO-02 extended-release capsules, when compared to placebo, in subjects with moderate to severe chronic low back pain.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Naltrexone
Oxycodone